Technical Analysis for AYTUZ - Aytu Bioscience Inc Wt Exp 11/02/2021

Grade Last Price % Change Price Change
grade F 0.0087 64.15% 0.0034
AYTUZ closed up 64.15 percent on Monday, January 27, 2020, on 1 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical AYTUZ trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 64.15%
Stochastic Reached Oversold Weakness 64.15%
Wide Bands Range Expansion 64.15%
Older signals for AYTUZ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Aytu is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. We are currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, urinary tract infections and male infertility. We currently market Natesto (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. We also currently market ProstaScint (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. We also market Primsol (trimethoprim hydrochloride) — the only FDA-approved trimethoprim-only oral solution for urinary tract infections. We have a focused pipeline, including MiOXSYSTM, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S.
Medicine RTT Pharmaceutical Organ Systems Alcohols Prostate Cancer Hormones Ketones Testosterone Urinary Tract Infection Androstanes Hypogonadism Testosterone Replacement Therapy Urinary Tract Infections U.S. Food And Drug Administration In Vitro Diagnostic Device Androgen Replacement Therapy Indium (111in) Capromab Pendetide Male Infertility Trimethoprim Only Oral Solution Urological Cancers

Is AYTUZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.41
52 Week Low 0.0007
Average Volume 37,951
200-Day Moving Average 0.0000
50-Day Moving Average 0.0096
20-Day Moving Average 0.0077
10-Day Moving Average 0.0078
Average True Range 0.0025
ADX 11.8
+DI 47.2464
-DI 36.5217
Chandelier Exit (Long, 3 ATRs ) 0.0065
Chandelier Exit (Short, 3 ATRs ) 0.0126
Upper Bollinger Band 0.0130
Lower Bollinger Band 0.0024
Percent B (%b) 0.59
BandWidth 137.6623
MACD Line -0.0008
MACD Signal Line -0.0009
MACD Histogram 0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0087
Resistance 3 (R3) 0.0087 0.0087 0.0087
Resistance 2 (R2) 0.0087 0.0087 0.0087 0.0087
Resistance 1 (R1) 0.0087 0.0087 0.0087 0.0087 0.0087
Pivot Point 0.0087 0.0087 0.0087 0.0087 0.0087
Support 1 (S1) 0.0087 0.0087 0.0087 0.0087 0.0087
Support 2 (S2) 0.0087 0.0087 0.0087 0.0087
Support 3 (S3) 0.0087 0.0087 0.0087
Support 4 (S4) 0.0087